financetom
Business
financetom
/
Business
/
What's Going On With Home Retailer Lowe's Shares After Raising Dividend By 5%?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Home Retailer Lowe's Shares After Raising Dividend By 5%?
May 31, 2024 10:17 AM

Lowe’s Companies, Inc. shares are trading slightly higher on Friday.

The company has declared a quarterly cash dividend of $1.15 per share, payable Aug. 7 to shareholders of record as of July 24.

This represents a 5% increase over the company’s previous dividend of $1.10 per share.

“Today’s dividend increase reflects the Board’s confidence in our growth strategy and commitment to disciplined capital allocation that delivers long-term shareholder value,” said Marvin R. Ellison, Lowe’s chairman, president and CEO.

Last week, the company reported better-than-expected first-quarter FY24 earnings. The company reported a first-quarter FY24 sales decline of 4.4% year-on-year to $21.364 billion, beating the analyst consensus estimate of $21.123 billion.

Lowe’s repurchased about 3.0 million shares for $743 million and paid $633 million in dividends in the quarter.

Since its public debut in 1961, Lowe’s has consistently issued quarterly cash dividends, with over 25 consecutive years of dividend increases.

According to Benzinga Pro, LOW stock has gained 8% in the past year. Investors can gain exposure to the stock via Northern Lights Fund Trust IV FMC Excelsior Focus Equity ETF and VanEck Retail ETF ( RTH ) .

Lowe’s sees FY24 revenue of $84 billion-$85 billion, against the Street view of $84.51 billion.

Lowe’s expects FY24 EPS of $12.00-$12.30 against the consensus of $12.21. LOW expects FY24 comparable sales to decline 2% – 3%.

Price Action: LOW shares are trading higher by 0.72% to $217.01 at last check Friday.

Read Next: Chewy Impresses With Strong Q1 Results; Analysts Envision Stabilized Customer Growth And Enhanced Profitability Ahead

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved